1 / 10

A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD

A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of Medicine Seoul, Korea. Opening the Door to Targeted Therapy in Gastric Cancer. Phase 3 trial results with 2 biologic agents recently reported

jasonmitchell
Download Presentation

A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of MedicineAsan Medical CenterUniversity of Ulsan College of MedicineSeoul, Korea

  2. Opening the Door to Targeted Therapy in Gastric Cancer • Phase 3 trial results with 2 biologic agents recently reported • With ToGA trial, trastuzumab plus chemotherapy became new standard of care • Highly important to select patients mostly likely to benefit from trastuzumab

  3. Selecting Patients for Trastuzumab Therapy in Gastric Cancer • In ToGA, 22% of patients were HER2+1 • Real-life HER2+ rate estimated to be 10% to 15% • ToGA subgroup analysis suggested patients with HER2 IHC 2+/FISH+ or IHC 3+ benefit most from trastuzumab treatment2 • HER2 testing algorithm recommended FISH = fluorescence in situ hybridization; HER2 = human epidermal growth factor receptor 2; IHC = immunohistochemistry 1. Chung H et al. Eur J Cancer Suppl .2009; 7:364. 2. Van Cutsem E et al. J Clin Oncol. 2009; 27[Suppl15S]:Abstract 4509.

  4. Recommended HER2 Testing Algorithm in Metastatic Gastric and Gastroesophageal Junction Cancer Patient tumor sample IHC 0 1+ 2+ 3+ FISH Important to test secondary and resected tumors, as they may differ in HER2 expression – + Eligible for trastuzumab Trastuzumab EU SmPC: http://www.ema.europa.eu/humandocs/PDFs/EPAR/Herceptin/emea-combined-h278en.pdf.

  5. AVAGAST: A Randomized, Double-Blind, Placebo-Controlled, Phase-3 Study Capecitabine*/cisplatin (XP) + placebo q3w Locally advanced or metastatic gastric cancer R Capecitabine*/cisplatin (XP) + bevacizumab q3w Stratification Factors: Geographic region Fluoropyrimidine backbone Disease status *5-FU also allowed if capecitabine contraindicatedCapecitabine 1000mg/m2 oral bid, d1–14, 1-week restCisplatin 80mg/m2 d1Bevacizumab 7.5 mg/kg d1Maximum of 6 cycles of cisplatinCapecitabine and bevacizumab/placebo until disease progression Kang Y-K et al. J Clin Oncol. 2010;28[18S]:Abstr LBA4007.

  6. AVAGAST Primary Endpoint: Overall Survival XP + placebo XP + bevacizumab 1.0 0.9 0.8 HR = 0.87 95% CI 0.73–1.03 P = .1002 0.7 0.6 12.1 0.5 Survival rate 0.4 10.1 0.3 0.2 0.1 0.0 12 0 15 18 21 24 3 9 6 Number at risk Study month 54 50 0 0 XP + Placebo XP + Bev 387 387 343 355 271 291 204 232 146 178 98 104 15 19 CI = confidence interval; HR = hazard ratioKang, et al. J Clin Oncol. 2010;28[18S]:Abstract LBA4007.

  7. AVAGAST Secondary Endpoints: PFS and ORR 1.0 0.8 0.6 0.4 0.2 0 XP + placebo XP + bevacizumab 6.7 Survival rate 5.3 HR = 0.8095% CI 0.68–0.93P = 0.0037 0 3 6 9 12 15 18 21 24 Study month PFS = progression-free survival; ORR = overall response rateKang et al. J Clin Oncol. 2010;28[18S]:Abstract LBA4007.

  8. AVAGAST: Areas for Further Study • Although bevacizumab did not meet primary endpoint of OS, secondary endpoints of PFS and ORR were significantly improved • Further study warranted for bevacizumab in gastric cancer • Efficacy of bevacizumab varied by geographic region • OS was longest in Asia, but benefit was the smallest • OS was shortest in Pan-America, but benefit was the largest

  9. Trastuzumab Signal transduction cascade blocked Apoptosis Proliferation Gene transcription/cell cycle Invasion/metastasis Angiogenesis Multiple Targets and Agents in Gastric Cancer Panitumumab Cetuximab EGFR HER2 Gefitinib Ras Bevacizumab Erlotinib SOS Raf Grb2 PI-3 kinase VEGF MEK Lapatinib STAT MAPK Akt Ramucirumab Receptor MoAb internalisation mTOR2 mTOR1 Everolimus

  10. Conclusions • Numerous targeted agents are being investigated in gastric cancer • To date, trastuzumab is the only targeted agent shown to improve OS in patients with advanced gastric cancer • Important to test HER2 status in all patients with advanced gastric cancer

More Related